MCID: RNL077
MIFTS: 47

Renal Fibrosis

Categories: Nephrological diseases

Aliases & Classifications for Renal Fibrosis

MalaCards integrated aliases for Renal Fibrosis:

Name: Renal Fibrosis 12 54 15 17 71

Classifications:



External Ids:

Disease Ontology 12 DOID:0050855
UMLS 71 C0151650

Summaries for Renal Fibrosis

Disease Ontology : 12 A kidney disease that is characterized by progressive detrimental connective tissue deposition of the kidney parenchyma leading to deterioration of renal function.

MalaCards based summary : Renal Fibrosis is related to ureteral obstruction and obstructive nephropathy. An important gene associated with Renal Fibrosis is CCN2 (Cellular Communication Network Factor 2), and among its related pathways/superpathways are TGF-Beta Pathway and PAK Pathway. The drugs Spironolactone and Tacrolimus have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and bone, and related phenotypes are Reduced mammosphere formation and cardiovascular system

Related Diseases for Renal Fibrosis

Diseases related to Renal Fibrosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 225)
# Related Disease Score Top Affiliating Genes
1 ureteral obstruction 31.9 TGFB1 NR3C2 ENG BMP7 BMP6 AGTR1
2 obstructive nephropathy 31.6 TGFB1 SMAD3 REN CCL2
3 microvascular complications of diabetes 3 31.5 TGFB1 REN MIR21 CCN2 BMP6 AGTR1
4 chronic kidney disease 31.3 TGFB1 SERPINE1 REN NR3C2 CCN2 CCL2
5 glomerulonephritis 31.2 TGFB1 CCN2 CCL2 AGTR1
6 iga glomerulonephritis 31.1 REN MIR214 AGTR1
7 kidney disease 30.9 TGFB1 SERPINE1 REN NR3C2 CCN2 CCL2
8 pulmonary fibrosis 30.6 TGFB1 SMAD3 SERPINE1 CCN2 CCL2 BMP6
9 crescentic glomerulonephritis 30.5 SERPINE1 CCN2 CCL2
10 idiopathic interstitial pneumonia 30.5 TGFB1 SMAD3 SERPINE1 MIR214 MIR21 CCN2
11 hypertrophic scars 30.4 TGFB1 SMAD3 BMP6
12 nephrosclerosis 30.4 TGFB1 NR3C2 CCN2 CCL2 BMP7 AGTR1
13 renal hypertension 30.4 REN MIR200B AGTR1
14 collagen disease 30.3 SMAD3 MIR21 CCN2
15 urinary tract obstruction 30.2 TGFB1 SMAD3 SERPINE1 REN CDH1 CCN2
16 posterior urethral valves 30.2 TGFB1 AGTR1
17 vesicoureteral reflux 1 30.2 TGFB1 REN AGTR1
18 autosomal dominant polycystic kidney disease 30.0 TGFB1 REN CDH1 CCL2 AGTR1
19 kidney cancer 29.8 SERPINE1 MIR29C MIR214 MIR21 MIR200B MAPK8
20 vascular disease 29.7 TGFB1 SERPINE1 REN MIR214 MIR21 ENG
21 diabetes mellitus 29.6 TGFB1 SERPINE1 REN NR3C2 MAPK8 CCN2
22 dilated cardiomyopathy 29.6 TGFB1 SERPINE1 REN NR3C2 MIR214 CCL2
23 connective tissue disease 29.6 SMAD3 MIR29C MIR214 MIR21 MIR200B CCN2
24 pulmonary fibrosis, idiopathic 29.4 TGFB1 SMAD3 SERPINE1 MIR214 MIR21 MAPK8
25 diabetes mellitus, noninsulin-dependent 29.3 SERPINE1 REN NR3C2 MIR29C MIR21 MAPK8
26 hypertension, essential 29.2 TGFB1 SMAD3 SERPINE1 REN NR3C2 MIR21
27 nephronophthisis 20 11.1
28 fibrosis of extraocular muscles, congenital, 1 11.0
29 pauci-immune glomerulonephritis 10.7 CCN2 BMP7
30 compensatory emphysema 10.7 CCN2 BMP7
31 microvascular complications of diabetes 4 10.7
32 microvascular complications of diabetes 6 10.7
33 microvascular complications of diabetes 7 10.7
34 keloid disorder 10.7 TGFB1 SMAD3 BMP6
35 cholecystolithiasis 10.7 TGFB1 CCN2 BMP6
36 nephrogenic systemic fibrosis 10.7 TGFB1 SMAD3 CCN2
37 urethral stricture 10.6 TGFB1 MIR21 CCN2
38 end stage renal failure 10.6
39 trachoma 10.6 TGFB1 ENG CCN2
40 kidney hypertrophy 10.6 TGFB1 REN CCN2
41 peyronie's disease 10.6 TGFB1 SMAD3 CCL2
42 oral submucous fibrosis 10.6 TGFB1 ENG CDH1
43 malignant secondary hypertension 10.6 REN AGTR1
44 autoimmune myocarditis 10.6 CCL2 AGTR1
45 central serous chorioretinopathy 10.6 SERPINE1 NR3C2
46 nonspecific interstitial pneumonia 10.6 TGFB1 MIR21 CCL2
47 localized scleroderma 10.6 TGFB1 SMAD3 CCN2 BMP6
48 vitreoretinopathy, neovascular inflammatory 10.6 TGFB1 CCN2 CCL2
49 spastic paraplegia 3, autosomal dominant 10.6 SMAD3 CDH1 CCN2 BMP7
50 pulmonary arterial hypertension associated with congenital heart disease 10.6 ENG CCN2

Graphical network of the top 20 diseases related to Renal Fibrosis:



Diseases related to Renal Fibrosis

Symptoms & Phenotypes for Renal Fibrosis

GenomeRNAi Phenotypes related to Renal Fibrosis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 AGTR1 CCL2 CDH1 MAPK8 NR3C2 RGCC

MGI Mouse Phenotypes related to Renal Fibrosis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.25 AGTR1 BMP7 CCN2 CDH1 ENG MAPK8
2 growth/size/body region MP:0005378 10.13 AGTR1 BMP6 BMP7 CCN2 CDH1 ENG
3 embryo MP:0005380 10.02 BMP7 CCN2 CDH1 ENG MAPK8 RGCC
4 digestive/alimentary MP:0005381 10.01 BMP7 CCN2 CDH1 ENG MAPK8 SMAD3
5 hematopoietic system MP:0005397 10 AGTR1 BMP7 ENG MAPK8 NR3C2 REN
6 immune system MP:0005387 9.9 AGTR1 BMP7 CCL2 CDH1 MAPK8 REN
7 mortality/aging MP:0010768 9.8 AGTR1 BMP7 CCN2 CDH1 ENG MAPK8
8 renal/urinary system MP:0005367 9.23 AGTR1 BMP7 MAPK8 NR3C2 REN SERPINE1

Drugs & Therapeutics for Renal Fibrosis

Drugs for Renal Fibrosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 73)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
2
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
3
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
4
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
5
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
6
Procaine Approved, Investigational, Vet_approved Phase 4 59-46-1 4914
7
Mycophenolic acid Approved Phase 4 24280-93-1 446541
8
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
9
rituximab Approved Phase 4 174722-31-7 10201696
10
Empagliflozin Approved Phase 4 864070-44-0
11
Canagliflozin Approved Phase 4 842133-18-0
12 Anti-Bacterial Agents Phase 4
13 Anti-Infective Agents Phase 4
14 Pharmaceutical Solutions Phase 4
15 Calcineurin Inhibitors Phase 4
16 Mineralocorticoids Phase 4
17 Hormone Antagonists Phase 4
18 Natriuretic Agents Phase 4
19 Mineralocorticoid Receptor Antagonists Phase 4
20 Hormones Phase 4
21 Diuretics, Potassium Sparing Phase 4
22 diuretics Phase 4
23 Antitubercular Agents Phase 4
24 Antibiotics, Antitubercular Phase 4
25 Antifungal Agents Phase 4
26 Immunosuppressive Agents Phase 4
27 Giapreza Phase 4
28 Angiotensinogen Phase 4
29 Angiotensin-Converting Enzyme Inhibitors Phase 4
30 Antineoplastic Agents, Immunological Phase 4
31 Vasoconstrictor Agents Phase 4
32 Immunoglobulins Phase 4
33 Antirheumatic Agents Phase 4
34 Omega 3 Fatty Acid Phase 4
35 Immunoglobulin A Phase 4
36 Antibodies Phase 4
37 Immunologic Factors Phase 4
38 Sodium-Glucose Transporter 2 Inhibitors Phase 4
39 Hypoglycemic Agents Phase 4
40
Ramipril Approved Phase 3 87333-19-5 5362129
41
Eplerenone Approved Phase 3 107724-20-9 150310 443872
42 Antihypertensive Agents Phase 3
43
Losartan Approved Phase 2 114798-26-4 3961
44
Valsartan Approved, Investigational Phase 2 137862-53-4 60846
45
Benazepril Approved, Investigational Phase 2 86541-75-5 5362124
46
Atorvastatin Approved Phase 2 134523-00-5 60823
47
Adalimumab Approved Phase 2 331731-18-1 16219006
48
Rosiglitazone Approved, Investigational Phase 2 122320-73-4 77999
49
Lisinopril Approved, Investigational Phase 2 83915-83-7, 76547-98-3 5362119
50 Anti-Arrhythmia Agents Phase 2

Interventional clinical trials:

(show all 28)
# Name Status NCT ID Phase Drugs
1 The Effects of Spironolactone on Calcineurin Inhibitor Induced Nephrotoxicity Unknown status NCT01602861 Phase 4 Spironolactone;placebo
2 Impact of a Mineralocorticoid Receptor Antagonist on Chronic Histological Changes in Renal Allograft Unknown status NCT01510795 Phase 4 spironolactone
3 Phase 4 Study: Comparison of Myfortic and Early Rapamycin Conversion vs. Low-Dose Tacrolimus in Preventing Acute Rejection and Chronic Allograft Fibrosis: A Protocol Biopsy Directed Approach Unknown status NCT00896012 Phase 4 Rapamune (sirolimus/rapamycin);Tacrolimus
4 A Multicenter, Randomized, Prospective, Open-Label Trial of Rituximab in the Treatment of Progressive IgA Nephropathy Completed NCT00498368 Phase 4 Intravenous Rituximab;ACE/ARB
5 Effects of SGLT2 Inhibition Treatment on Different Levels of Albuminuria in Patients With Type 2 Diabetes: a Prospective Interventional Study Recruiting NCT04127084 Phase 4 SGLT2 Inhibition
6 Early Prospective Therapy Trial to Delay Renal Failure in Children With Alport Syndrome Unknown status NCT01485978 Phase 3 Ramipril;placebo to ramipril;Ramipril
7 Prospective and Open Label Study With Blind End Point Evaluation on the Effect of Mineralocorticoid Receptor Inhibition on Endothelial Function of the Micro- and Macrovasculature in Patients With Metabolic Syndrome Completed NCT01319344 Phase 3 Eplerenone
8 Bioprofiling Response to Mineralocorticoid Receptor Antagonists for the Prevention of Heart Failure. A Proof of Concept Clinical Trial Within the EU FP 7 (European Union FP7) "HOMAGE" Programme " Heart OMics in AGing " Completed NCT02556450 Phase 2 Spironolacton
9 Effects of an Intensified Treatment With ACE-inhibitors, Angiotensin II Receptor Antagonists and Statins in Alport Syndrome Completed NCT00309257 Phase 2 ACE I, ATA II and Statins;Benazepril, Valsartan and Fluvastatin
10 Novel Therapies for Resistant Focal Segmental Glomerulosclerosis Completed NCT00814255 Phase 2 Adalimumab;Lisinopril, losartan, and atorvastatin;galactose
11 Phase III, Single-Center, Open Label, Trial Evaluating the Safety and Efficacy of PectaSol-C Modified Citrus Pectin on PSA Kinetics in Prostate Cancer in the Setting of Serial Increases in PSA Recruiting NCT01681823 Phase 2
12 A Trial of Doxycycline in Renal Disease (ADORE) Active, not recruiting NCT02753426 Phase 1 Doxycycline;Placebo (for Doxycycline)
13 Interest Of Renal Elastography In Children As A Diagnostic Tool Of Renal Fibrosis: Confrontation To Histological Features Of Renal Biopsies Unknown status NCT01613625
14 Study of Urinary Angiotensinogen as a Marker to Warn the Deterioration of Renal Function in CKD Patients Early. Unknown status NCT01118494
15 The Role of Nox2 in CNI-Induced Renal Fibrosis Completed NCT01674465
16 The Effect of Percutaneous Nephrostomy Application on Obstructed Kidneys With Relative Function of 10% or Less In Technetium-99m Dimercaptosuccinic Acid (DMSA) Scintigraphy Completed NCT03936673
17 Prospective Multicenter Study to Assess the Predictive Value of PIIINP and Urinary NGAL in Renal Function Recovery During Acute Tubular Necrosis Completed NCT02889575
18 Non-invasive Diagnosis of Chronic Kidney Disease in Renal Transplants Kidney Transplanted Using Ultrasound Functional Imaging Completed NCT02201537
19 Evaluation of the Effects of a Probiotic Formulation in Hemodialysis Patients Completed NCT03066921
20 Kidney Disease Biomarkers Completed NCT00255398
21 Angiotensin II Antagonism of TGF-Beta 1: A Candesartan Dose - TGF-Beta 1 Response Relationship Study Completed NCT00320970 Candesartan
22 Multi-center Controlled Clinical Trials in Alport Syndrome-A Feasibility Study Completed NCT01696253
23 Application of Ultrasound Integrated Precision Diagnosis Technology in Prevention of Kidney Disease and Its Progress Recruiting NCT04044404
24 Telmisartan Promotes the Differentiation of Monocytes Into Macrophages M2 in Diabetic Nephropathy? Recruiting NCT02768948 telmisartan during 6 months;Losartan during 6 months
25 Multicenter, Prospective Observational Study to Identify and Validate a Composite of Urinary Exosomal Biomarkers for Kidney Allograft Tubulointerstitial Fibrosis Recruiting NCT03870542
26 Association Between Urinary and Serum Levels of miRNA 192 and miRNA 25 and Glomerular Filtration and Albuminuria in Patients With and Without Type 2 Diabetes. Recruiting NCT04176276
27 Magnetic Resonance Elastography of Transplanted Kidney (GREFFE_ELASTO IRM) Recruiting NCT03918161
28 A Randomised Controlled Trial of the Effect of Dietary Salt Reduction on Blood Pressure and Other Cardiovascular Parameters in Kidney Transplant Recipients Recruiting NCT03373500

Search NIH Clinical Center for Renal Fibrosis

Genetic Tests for Renal Fibrosis

Anatomical Context for Renal Fibrosis

MalaCards organs/tissues related to Renal Fibrosis:

40
Kidney, Endothelial, Bone, Heart, Liver, T Cells, Monocytes

Publications for Renal Fibrosis

Articles related to Renal Fibrosis:

(show top 50) (show all 3853)
# Title Authors PMID Year
1
Lefty A attenuates the TGF-beta1-induced epithelial to mesenchymal transition of human renal proximal epithelial tubular cells. 54 61
20157767 2010
2
Renal proximal tubular dysfunction is a major determinant of urinary connective tissue growth factor excretion. 54 61
20237235 2010
3
Oxidative stress mediates nephropathy in type Ia glycogen storage disease. 54 61
20195241 2010
4
Connective tissue growth factor-(CTGF, CCN2)--a marker, mediator and therapeutic target for renal fibrosis. 54 61
19955828 2010
5
EMT and TGF-beta in renal fibrosis. 54 61
20036943 2010
6
Hepatocyte growth factor suppresses transforming growth factor-beta-1 and type III collagen in human primary renal fibroblasts. 54 61
19858036 2009
7
Differential regulation of E-cadherin and alpha-smooth muscle actin by BMP 7 in human renal proximal tubule epithelial cells and its implication in renal fibrosis. 54 61
19741012 2009
8
Transforming growth factor-beta2 upregulates sphingosine kinase-1 activity, which in turn attenuates the fibrotic response to TGF-beta2 by impeding CTGF expression. 54 61
19657322 2009
9
Sphingosine kinase-1: a potential mediator of renal fibrosis. 54 61
19789541 2009
10
IL-18 neutralization ameliorates obstruction-induced epithelial-mesenchymal transition and renal fibrosis. 54 61
19536084 2009
11
Mitogen activated protein kinases in renal fibrosis. 54 61
19482693 2009
12
[Molecular mechanisms of tissue fibrosis]. 54 61
19564712 2009
13
CTGF and chronic kidney fibrosis. 54 61
19482689 2009
14
BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition in human renal proximal tubular epithelial cells. 54 61
19557718 2009
15
Transforming growth factor-beta1 in congenital ureteropelvic junction obstruction: diagnosis and follow-up. 54 61
19538767 2009
16
[Dracorhodin perchlorate inhibit high glucose-induced connective tissue growth factor formation in human mesangial cells]. 54 61
19623991 2009
17
Induction of hepatocyte growth factor production in human dermal fibroblasts and their proliferation by the extract of bitter melon pulp. 54 61
19223201 2009
18
Prediction of chronic allograft damage index of renal allografts using serum level of plasminogen activator inhibitor-1. 54 61
19220364 2009
19
Transforming growth factor beta and excess burden of renal disease. 54 61
19768163 2009
20
EPA and DHA suppress AngII- and arachidonic acid-induced expression of profibrotic genes in human mesangial cells. 54 61
19229829 2009
21
Increased E-cadherin expression in the ligated kidney following unilateral ureteric obstruction. 54 61
18818685 2009
22
Relaxin and the progression of kidney disease. 54 61
19077683 2009
23
Albumin induces interleukin-6 release from primary human proximal tubule epithelial cells. 54 61
19034873 2008
24
Impact of plasminogen activator inhibitor-1 gene polymorphisms on primary membranous nephropathy. 54 61
18495745 2008
25
Bone morphogenetic protein-7 and connective tissue growth factor: novel targets for treatment of renal fibrosis? 54 61
18266088 2008
26
Reversal of experimental renal fibrosis by BMP7 provides insights into novel therapeutic strategies for chronic kidney disease. 54 61
18446379 2008
27
IHG-1 amplifies TGF-beta1 signaling and is increased in renal fibrosis. 54 61
18508967 2008
28
Angiotensin II activates the Smad pathway during epithelial mesenchymal transdifferentiation. 54 61
18509316 2008
29
A natural PPAR-gamma agonist, 15-deoxy-delta 12,14-prostaglandin J2, may act as an enhancer of PAI-1 in human proximal renal tubular cells under hypoxic and inflammatory conditions. 54 61
18367541 2008
30
Tissue inhibitor of metalloproteinase-1 exacerbated renal interstitial fibrosis through enhancing inflammation. 54 61
18326884 2008
31
Prorenin and (pro)renin receptor: a review of available data from in vitro studies and experimental models in rodents. 54 61
18376005 2008
32
Smad7 as a therapeutic agent for chronic kidney diseases. 54 61
18508563 2008
33
The renin-angiotensin system contributes to renal fibrosis through regulation of fibrocytes. 54 61
18327089 2008
34
Transforming growth factor-beta/connective tissue growth factor axis in the kidney. 54 61
17300978 2008
35
Inhibitory effect of interleukin-1beta on angiotensin II-induced connective tissue growth factor and type IV collagen production in cultured mesangial cells. 54 61
17989112 2008
36
BMP-7 does not protect against bleomycin-induced lung or skin fibrosis. 54 61
19112509 2008
37
A new look at platelet-derived growth factor in renal disease. 54 61
18077793 2008
38
Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis. 54 61
17274978 2007
39
TNF-alpha, but not IFN-gamma, regulates CCN2 (CTGF), collagen type I, and proliferation in mesangial cells: possible roles in the progression of renal fibrosis. 54 61
17376761 2007
40
Role of ERK1/2 and PI3-K in the regulation of CTGF-induced ILK expression in HK-2 cells. 54 61
17498677 2007
41
Plasminogen activator inhibitor-1 production is pathogenetic in experimental murine diabetic renal disease. 54 61
17415547 2007
42
Cell phenotype-specific down-regulation of Smad3 involves decreased gene activation as well as protein degradation. 54 61
17400544 2007
43
Functional renin receptors in renal mesangial cells. 54 61
17442225 2007
44
TGF-beta1 in chronic allograft nephropathy following renal transplantation. 54 61
17514622 2007
45
Role of connective tissue growth factor in extracellular matrix degradation in renal tubular epithelial cells. 54 61
17393107 2007
46
The TGFbeta1-induced fibronectin in human renal proximal tubular epithelial cells is p38 MAP kinase dependent and Smad independent. 54 61
17347580 2007
47
Ca2+ but not H2O2 modulates GRE-element activation by the human mineralocorticoid receptor in HEK cells. 54 61
17113706 2007
48
TIMP-1 promotes age-related renal fibrosis through upregulating ICAM-1 in human TIMP-1 transgenic mice. 54 61
17167153 2006
49
Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. 54 61
16914537 2006
50
Hepatocyte growth factor: new arsenal in the fights against renal fibrosis? 54 61
16838037 2006

Variations for Renal Fibrosis

Expression for Renal Fibrosis

Search GEO for disease gene expression data for Renal Fibrosis.

Pathways for Renal Fibrosis

Pathways related to Renal Fibrosis according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.47 TGFB1 SMAD3 MAPK8 CDH1 CCN2 CCL2
2
Show member pathways
13.23 TGFB1 SMAD3 MAPK8 CDH1 CCN2 CCL2
3
Show member pathways
12.85 TGFB1 REN MAPK8 CCN2 CCL2 BMP7
4 12.75 TGFB1 SMAD3 MAPK8 CDH1 AGTR1
5
Show member pathways
12.37 TGFB1 SPHK1 SMAD3 BMP7
6
Show member pathways
12.34 TGFB1 MAPK8 CDH1 CCN2 BMP7 BMP6
7 11.96 TGFB1 SMAD3 SERPINE1 ENG CCN2 BMP7
8 11.94 SPHK1 SMAD3 SERPINE1 CDH1 CCN2 AGTR1
9 11.83 TGFB1 SMAD3 MAPK8 ENG
10 11.81 TGFB1 SMAD3 BMP7 BMP6
11 11.77 TGFB1 REN ENG CCL2
12 11.73 TGFB1 SMAD3 SERPINE1 MAPK8 CCL2 AGTR1
13
Show member pathways
11.71 TGFB1 REN NR3C2 AGTR1
14 11.69 TGFB1 SMAD3 SERPINE1 CDH1 CCN2 BMP7
15
Show member pathways
11.68 TGFB1 SMAD3 MAPK8
16 11.64 TGFB1 SMAD3 SERPINE1
17 11.61 TGFB1 SMAD3 MAPK8 BMP7 BMP6
18 11.59 SMAD3 SERPINE1 ENG
19 11.59 TGFB1 BMP7 BMP6
20 11.56 TGFB1 CCN2 CCL2 BMP7
21 11.48 TGFB1 SMAD3 CCN2
22 11.47 TGFB1 SMAD3 MAPK8
23 11.47 TGFB1 SMAD3 SERPINE1 ENG
24 10.93 TGFB1 SMAD3 CDH1
25 10.88 TGFB1 MAPK8 CDH1 CCN2 CCL2 BMP7
26 10.5 SMAD3 SERPINE1 MAPK8 ENG CCN2 AGTR1

GO Terms for Renal Fibrosis

Cellular components related to Renal Fibrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.32 TGFB1 SERPINE1 REN MIR29C MIR21 ENG

Biological processes related to Renal Fibrosis according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.22 TGFB1 SMAD3 SERPINE1 RGCC ENG BMP7
2 negative regulation of apoptotic process GO:0043066 10.12 SPHK1 SMAD3 MIR21 MIR200B MAPK8
3 positive regulation of cell proliferation GO:0008284 10.08 TGFB1 SPHK1 MIR21 MIR200B CCN2 BMP6
4 inflammatory response GO:0006954 10.06 TGFB1 SPHK1 CCL2 BMP6 AGTR1
5 gene silencing by miRNA GO:0035195 10.02 MIR29C MIR214 MIR21 MIR200B
6 positive regulation of apoptotic process GO:0043065 10.01 TGFB1 MIR29C MIR21 MIR200B MAPK8 BMP7
7 positive regulation of cell migration GO:0030335 10 TGFB1 SPHK1 SMAD3 MIR21
8 angiogenesis GO:0001525 10 SERPINE1 ENG CCN2 CCL2
9 negative regulation of cell proliferation GO:0008285 10 TGFB1 SMAD3 RGCC MIR29C MIR214 MIR21
10 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.99 TGFB1 MIR21 CCN2 CCL2
11 positive regulation of protein phosphorylation GO:0001934 9.97 TGFB1 MIR21 ENG CCN2
12 cellular response to lipopolysaccharide GO:0071222 9.96 SERPINE1 MIR21 MAPK8 CCL2
13 positive regulation of angiogenesis GO:0045766 9.94 SPHK1 SERPINE1 MIR21 ENG
14 ossification GO:0001503 9.9 CCN2 BMP7 BMP6
15 kidney development GO:0001822 9.9 REN BMP7 BMP6 AGTR1
16 response to organic substance GO:0010033 9.89 TGFB1 REN CDH1
17 positive regulation of inflammatory response GO:0050729 9.89 SERPINE1 MIR21 AGTR1
18 negative regulation of angiogenesis GO:0016525 9.88 RGCC MIR29C MIR214 MIR21 MIR200B
19 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.86 MIR29C MIR21 CCL2
20 positive regulation of osteoblast differentiation GO:0045669 9.85 MIR21 BMP7 BMP6
21 cell development GO:0048468 9.85 TGFB1 BMP7 BMP6
22 cellular response to mechanical stimulus GO:0071260 9.85 TGFB1 MAPK8 ENG BMP6
23 positive regulation of stress fiber assembly GO:0051496 9.83 SMAD3 RGCC CCN2
24 regulation of MAPK cascade GO:0043408 9.83 TGFB1 REN BMP7 BMP6
25 SMAD protein signal transduction GO:0060395 9.81 TGFB1 SMAD3 BMP7 BMP6
26 negative regulation of blood vessel endothelial cell migration GO:0043537 9.8 TGFB1 RGCC MIR200B
27 positive regulation of pathway-restricted SMAD protein phosphorylation GO:0010862 9.8 TGFB1 ENG BMP7 BMP6
28 ureteric bud development GO:0001657 9.79 TGFB1 SMAD3 BMP7
29 positive regulation of protein import into nucleus GO:0042307 9.79 TGFB1 SMAD3 CDH1
30 positive regulation of peptidyl-threonine phosphorylation GO:0010800 9.77 TGFB1 SPHK1 BMP7
31 BMP signaling pathway GO:0030509 9.77 TGFB1 MIR21 ENG BMP7 BMP6
32 positive regulation of cell cycle arrest GO:0071158 9.76 TGFB1 RGCC MIR200B
33 regulation of transforming growth factor beta receptor signaling pathway GO:0017015 9.73 TGFB1 SMAD3 ENG
34 positive regulation of bone mineralization GO:0030501 9.73 TGFB1 SMAD3 BMP7 BMP6
35 negative regulation of cell migration GO:0030336 9.73 SERPINE1 MIR29C MIR214 MIR21 ENG CDH1
36 positive regulation of interleukin-17 production GO:0032740 9.72 TGFB1 SPHK1
37 mesonephros development GO:0001823 9.71 REN BMP7
38 lens fiber cell differentiation GO:0070306 9.71 TGFB1 SMAD3
39 positive regulation of SMAD protein signal transduction GO:0060391 9.71 TGFB1 BMP6
40 positive regulation of vascular permeability GO:0043117 9.7 TGFB1 BMP6
41 salivary gland morphogenesis GO:0007435 9.7 TGFB1 BMP7
42 negative regulation of gene expression GO:0010629 9.7 TGFB1 MIR29C MIR214 MIR21 MIR200B ENG
43 negative regulation of cell-cell adhesion mediated by cadherin GO:2000048 9.69 RGCC BMP6
44 positive regulation of vascular smooth muscle cell differentiation GO:1905065 9.69 MIR21 ENG
45 negative regulation of cardiac muscle hypertrophy in response to stress GO:1903243 9.68 SMAD3 MIR214
46 SMAD protein complex assembly GO:0007183 9.67 TGFB1 SMAD3
47 connective tissue development GO:0061448 9.65 TGFB1 CCN2
48 regulation of striated muscle tissue development GO:0016202 9.65 TGFB1 SMAD3
49 extracellular matrix constituent secretion GO:0070278 9.64 ENG CCN2
50 regulation of binding GO:0051098 9.63 TGFB1 SMAD3

Molecular functions related to Renal Fibrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.67 MIR29C MIR214 MIR21 MIR200B
2 cytokine activity GO:0005125 9.56 TGFB1 CCL2 BMP7 BMP6
3 type I transforming growth factor beta receptor binding GO:0034713 9.32 TGFB1 ENG
4 growth factor activity GO:0008083 9.26 TGFB1 CCN2 BMP7 BMP6
5 type II transforming growth factor beta receptor binding GO:0005114 9.16 TGFB1 ENG
6 transforming growth factor beta receptor binding GO:0005160 8.92 TGFB1 SMAD3 BMP7 BMP6

Sources for Renal Fibrosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....